You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,447,469


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,447,469
Title:Identification of genetic variants
Abstract: The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or absence of an allelic variant indicates whether the subject is more or less likely to be responsive to VEGF-based therapy.
Inventor(s): Lamont; John V. (Crumlin, GB)
Assignee: RANDOX LABORATORIES LTD. (GB)
Application Number:14/323,775
Patent Claims:1. A method for administering a VEGF-based therapy to a subject, the method comprising administering a VEGF-based therapy selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione to a subject known to have an allelic variant selected from the group consisting of: i. rs6921438, wherein a guanine residue is present at base 323 of SEQ ID No.1 at one or both alleles, ii. rs4416670, wherein a thymine residue is present at base 221 of SEQ ID Not at one or both alleles, iii. rs6993770, wherein a thymine residue is absent at base 235 of SEQ ID No.3 at one or both alleles, and iv. rs10738760, wherein a guanine residue is present at 201 of SEQ ID No.4 at one or both alleles.

2. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs6921438, wherein a guanine residue is detected at base 323 of SEQ ID No.1 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

3. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs4416670, wherein a thymine residue is detected at base 221 of SEQ ID No.2 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

4. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs6993770, wherein a thymine residue is not detected at base 235 of SEQ ID No.3 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

5. A method for administering a VEGF-based therapy to a subject, the method comprising: screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of the allelic variant rs10738760, wherein a guanine residue is detected at 201 of SEQ ID No.4 at one or both alleles; and administering a VEGF-based therapy to the subject, wherein the VEGF-based therapy is selected from bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, pazopanib, and thiazolidinedione.

6. The method of claim 2, wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

7. The method of claim 3, wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

8. The method of claim 4, wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

9. The method of claim 5, wherein said screening comprises carrying out an in vitro assay with an array that identifies the presence or absence of the allelic variant.

10. The method of claim 2, further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

11. The method of claim 3, further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

12. The method of claim 4, further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

13. The method of claim 5, further comprising, prior to said screening, obtaining a biological sample from the subject and isolating nucleic acid from the biological sample, to obtain the nucleic acid sample.

14. The method of claim 10, wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5' fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

15. The method of claim 11, wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5' fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

16. The method of claim 12, wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5' fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

17. The method of claim 13, wherein said screening comprises polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), isothermic amplification, nucleic acid sequence based amplification (NASBA), 5' fluorescence nuclease assay, molecular beacon assay, or rolling-circle amplification.

18. The method of claim 14, wherein the biological sample is a blood sample.

19. The method of claim 15, wherein the biological sample is a blood sample.

20. The method of claim 16, wherein the biological sample is a blood sample.

21. The method of claim 17, wherein the biological sample is a blood sample.

Details for Patent 9,447,469

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2031-08-25
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 ⤷  Try a Trial 2031-08-25
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 ⤷  Try a Trial 2031-08-25
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.